Close
CDMO Safety Testing 2026
Novotech

Global market will reach $26 billion by 2020, says GBI Research

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

The Hidden Cost of Licensing in Biologic Drug Development

Royalties, milestone payments, and license fees are often treated as the cost of doing business in biopharma. But for early-stage biotech companies building toward an IND, these obligations can quietly reshape financial models, complicate investor conversations, and create downstream deal terms that are difficult to unwind. Here is what founders need to know.
- Advertisement -

The global market for drug delivery technologies will rise from $20 billion in 2015 to around $26 billion by 2020, according to business intelligence firm GBI Research.

The company’s latest report states that the emergence of new business models, emphasis on improving drug delivery, growing incidence of chronic diseases, increasing usage of complex medicines and significant technological advancements will continue to drive growth in the drug delivery technologies market to 2020.

North America remains the largest regional market for drug delivery technologies, with the US accounting for the largest market in terms of value and volume.

Deekshita Allavarapu, Analyst for GBI Research, states: “The size of the US market was estimated to be $6.2 billion in 2015 and is projected to grow at a compound annual growth rate (CAGR) of 4.3% from 2010 to reach $7.7 billion in 2020.

“The US drug delivery technologies market will continue to maintain its leading position in the global market during the forecast period due to a rapidly growing aging population, rising prevalence of chronic diseases and new product launches.”

GBI Research also states that Asia-Pacific (APAC) is expected to be the fastest-growing region over the forecast period, with the Indian market expanding at a CAGR of 7.3% from 2010 to 2020 and the Chinese market rising at a CAGR of 5.2% over the same period.

“The fast growth in APAC markets is attributed to the growing population, the rising prevalence of chronic diseases in the region and the need to address a wide range of unmet medical needs.”

– Comments provided by Deekshita Allavarapu, Analyst for GBI Research.
– Information based on GBI’s report: Global Drug Delivery Technologies.
– This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

About GBI Research
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets. GBI Research is a trading name of GlobalData plc.

For more information,
please contact our Press Office on 
+44 (0)161 359 5822 
pr@gbiresearch.com

 

Latest stories

Related stories

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

The Hidden Cost of Licensing in Biologic Drug Development

Royalties, milestone payments, and license fees are often treated as the cost of doing business in biopharma. But for early-stage biotech companies building toward an IND, these obligations can quietly reshape financial models, complicate investor conversations, and create downstream deal terms that are difficult to unwind. Here is what founders need to know.

Early Phase Decisions Drive Faster Drug Development

Strategic early-stage planning and rigorous regulatory readiness serve as the foundation for accelerating pharmaceutical timelines and optimizing long-term R&D efficiency.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »